<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770482</url>
  </required_header>
  <id_info>
    <org_study_id>PA13050</org_study_id>
    <nct_id>NCT02770482</nct_id>
  </id_info>
  <brief_title>Amyloid Beta-peptide 1-40 and Alzheimer's Disease</brief_title>
  <acronym>ADAB40</acronym>
  <official_title>Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal
      fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has
      justified its inclusion new diagnostic criteria. However, it can sometimes yield discordant
      results that are not discriminant (isolated variation in Ab42 or P-181 Tau). To answer this
      challenge, a new marker has been developed in recent years, namely amyloid beta-peptide 1-40
      (Aβ40). This marker reflects the patient's total amyloid deposits and is used to calculate
      the Aβ42/Aβ40 ratio. This ratio measures the relative variation of Aβ42 as compared to the
      total amyloid burden. Literature data on this topic are sparse and to date, no report has
      been published evaluating the utility of this marker in the diagnostic strategy for AD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of diagnostic certitude for AD (diagnosed cases)</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>AD Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>spinal fluid collection</intervention_name>
    <arm_group_label>AD Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients attending the Memory Clinic of Champagne-Ardennes for memory disorders, and

          -  Whose diagnostic work-up requires assessment of biomarkers present in the
             cerebrospinal fluid are considered eligible for inclusion in this study.

        Exclusion Criteria:

          -  Patients who do not have any social security coverage will not be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dementia</keyword>
  <keyword>biomarkers</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

